Influence of nucleated cell dose on overall survival of unrelated cord blood transplantation for patients with severe acquired aplastic anemia: A study by eurocord and the aplastic anemia working party of the european group for blood and marrow transplantation

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 1, 2011, Pages 78-85

  De Latour, Regis Peffault ^a   Purtill, Duncan ^a   Ruggeri, Annalisa ^a   Sanz, Guillermo ^b   Michel, Gerard ^c   Gandemer, Virginie ^d   Maury, Sebastien ^e   Kurtzberg, Joanne ^f   Bonfim, Carmen ^g   Aljurf, Mahmoud ^h   Gluckman, Eliane ^a   Socié, Gerard ^a   Passweg, Jakob ⁱ   Rocha, Vanderson ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c TIMONE HOSPITAL   (France)

^d Department of OncoPediatrics ^*  (France)

^e HENRI MONDOR HOSPITAL   (France)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^h King Faisal Specialist Center and Research Center   (Saudi Arabia)

ⁱ GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Acquired bone marrow failure; Alternative donor transplant

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; AGED; APLASTIC ANEMIA; ARTICLE; CHILD; CHIMERA; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE SEVERITY; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; FREEZING; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; OVERALL SURVIVAL; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRESCHOOL CHILD; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; SCHOOL CHILD; SEVERE APLASTIC ANEMIA; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 84858699230     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.06.011     Document Type: Article

References (47)

1. Horowitz MM. Current status of allogeneic bone marrow transplantation in acquired aplastic anemia. Semin Hematol. 2000;37: 30-42.
2. Frickhofen N, Rosenfeld SJ. Immunosuppressive treatment of aplastic anemia with antithymocyte globulin and cyclosporine. Semin Hematol. 2000;37:56-68.
3. Kojima S, Hibi S, Kosaka Y, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood. 2000;96:2049-2054.
4. Rosenfeld S, Follmann D, Nunez O, et al. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA. 2003;289:1130-1135.
5. Frickhofen N, Heimpel H, Kaltwasser JP, et al. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood. 2003;101:1236-1242.
6. Young NS, Scheinberg P, Calado RT. Aplastic anemia. Curr Opin Hematol. 2008;15:162-168.
7. Deeg HJ, O'Donnell M, Tolar J, et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood. 2006;108:1485-1491.
8. Maury S, Balere-Appert ML, Chir Z, et al. Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high-resolution HLA matching between donor and recipient. Haematologica. 2007;92:589-596.
9. Deeg HJ, Amylon ID, Harris RE, et al. Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. Biol Blood Marrow Transplant. 2001;7:208-215.
10. Kojima S, Matsuyama T, Kato S, et al. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Blood. 2002; 100:799-803.
11. Bacigalupo A, Socie G, Lanino E, et al. Fludarabine, Cyclophosphamide, Antithymocyte Globulin, with or without 2 Gy TBI, for alternative donor transplants in Acquired Aplastic Anemia (SAA): A report from the EBMT-SAA Working Party, Haematologica. 2010;95:976-982.
12. Kennedy-Nasser AA, Leung KS, Mahajan A, et al. Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biol Blood Marrow Transplant. 2006;12:1277-1284.
13. Young N, Bacigalupo A., Marsh J. Aplastic Anemia: Pathophysiology and Treatment. Biol Blood Marrow Transplant. 2009;S119-25.
14. Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med. 1998;339:1565-1577.
15. Sauter C, Barker JN. Unrelated donor umbilical cord blood transplantation for the treatment of hematologic malignancies. Curr Opin Hematol. 2008;15:568-575.
16. Neudorf SM, Blatt J, Corey S, et al. Graft failure after an umbilical cord blood transplant in a patient with severe aplastic anemia. Blood. 1995;85:2991-2992.
17. Lau FY, Wong R, Chui CH, et al. Successful engraftment in two adult patients with severe aplastic anemia using nonmyeloablative conditioning followed by unrelatedHLA-mismatched cord blood transplantation. J Hematother Stem Cell Res. 2001;10:309-311.
18. Mao P, Zhu Z, Wang H, et al. Sustained and stable hematopoietic donor-recipient mixed chimerism after unrelated cord blood transplantation for adult patients with severe aplastic anemia. Eur J Haematol. 2005;75:430-435.
19. Ohga S, Ichino K, Goto K, et al. Unrelated donor cord blood transplantation for childhood severe aplastic anemia after a modified conditioning. Pediatr Transplant. 2006;10:497-500.
20. Chan KW, McDonald L, Lim D, et al. Unrelated cord blood transplantation in children with idiopathic severe aplastic anemia. Bone Marrow Transplant. 2008;42:589-595.
21. Yoshimi A, Kojima S, Taniguchi S, et al. Unrelated cord blood transplantation for severe aplastic anemia. Biol Blood Marrow Transplant. 2008;14:1057-1063.
22. Gluckman E, Rocha V, Ionescu I, et al. Results of unrelated cord blood transplant in Fanconi anemia patients: risk factor analysis for engraftment and survival. Biol Blood Marrow Transplant. 2007; 13:1073-1082.
23. Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628-1633.
24. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHDGrading. Bone Marrow Transplant. 1995;15:825-828.
25. Byar DP. Cancer Clinical Trials: Methods and Practice. Oxford, UK: Oxford Medical Publications; 1988.
26. Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695-706.
27. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competive risk. Ann Stat. 1988;116:1141-1154.
28. Rocha V, Labopin M, Sanz G, et al. Transplants of umbilicalcord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med. 2004;351:2276-2285.
29. Rocha V, Gluckman E. Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors. Br J Haematol. 2009;147:262-274.
30. Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med. 2004;351:2265-2275.
31. Barker JN, Scaradavou A, Stevens CE. Combined effect of total nucleated cell dose and HLA-match on transplant outcome in 1061 cord blood recipients with hematological malignancies. Blood. 2009;115:1843-1849.
32. Stroncek DF, Rebulla P. Platelet transfusions. Lancet. 2007;370: 427-438.
33. Klein HG, Spahn DR, Carson JL. Red blood cell transfusion in clinical practice. Lancet. 2007;370:415-426.
34. Ades L, Mary JY, Robin M, et al. Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood. 2004; 103:2490-2497.
35. Takanashi M, Fujiwara K, Atsuta Y, et al. Anti-HLA antibodies in unrelated cord blood transplantation, Bone Marrow Transplantation. 2009;43, Sup 1 abstract 143.
36. Lawler M, McCann SR, Marsh JC, et al. Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post-SCT for SAA. Br J Haematol. 2009;144:933-945.
37. Bacigalupo A, Locatelli F, Lanino E, et al. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant. 2005; 36:947-950.
38. Georges GE, Storb R. Allogeneic Hematopoietic Cell Transplantation for Aplastic Anemia. Oxford, UK: Blackwell; 2004.
39. Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitorcell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998;16:2817-2824.
40. Kang HJ, Shin HY, Choi HS, et al. Fludarabine, cyclophosphamide plus thymoglobulin conditioning regimen for unrelated bone marrow transplantation in severe aplastic anemia. Bone Marrow Transplant. 2004;34:939-943.
41. Saavedra S, Sanz GF, Jarque I, et al. Early infections in adult patients undergoing unrelated donor cord blood transplantation. Bone Marrow Transplant. 2002;30:937-943.
42. Long GD, Laughlin M, Madan B, et al. Unrelated umbilical cord blood transplantation in adult patients. Biol Blood Marrow Transplant. 2003;9:772-780.
43. Safdar A, Rodriguez GH, De Lima MJ, et al. Infections in 100 cord blood transplantations: spectrum of early and late posttransplant infections in adult and pediatric patients 1996-2005. Medicine (Baltimore). 2007;86:324-333.
44. Komanduri KV, St John LS, de Lima M, et al. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood. 2007;110:4543-4551.
45. van Esser JW, Niesters HG, van der Holt B, et al. Prevention of Epstein-Barr virus lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood. 2002;99: 4364-4369.
46. Gartner BC, Schafer H, Marggraff K, et al. Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease. J Clin Microbiol. 2002;40:351-358.
47. Blaes AH, Cao Q, Wagner JE, et al. Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation, Biol Blood Marrow Transplant. 2010;16:287-291.